Drug Profile
Research programme: neurodegenerative disease protein therapeutics - Carisma Therapeutics
Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Eleven Biotherapeutics
- Developer Carisma Therapeutics
- Class Proteins
- Mechanism of Action Cytokine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peripheral nervous system diseases; Retinal disorders
Most Recent Events
- 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
- 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
- 21 Mar 2014 No development reported for Peripheral nervous system diseases in USA (unspecified route)